vs
CNB FINANCIAL CORP（CCNE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CNB FINANCIAL CORP的1.5倍（$127.1M vs $86.4M），CNB FINANCIAL CORP同比增速更快（45.5% vs 17.1%），CNB FINANCIAL CORP自由现金流更多（$58.7M vs $-26.7M），过去两年CNB FINANCIAL CORP的营收复合增速更高（26.3% vs 20.8%）
CNB金融集团（宾夕法尼亚州）是美国区域性银行控股企业，总部位于宾州，提供零售及商业银行服务，涵盖储蓄账户、个人及商业贷款、财富管理等产品，服务区域覆盖宾州、俄亥俄州及西弗吉尼亚州，客户包括个人消费者和中小微企业。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CCNE vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$86.4M
营收增速更快
CCNE
高出28.4%
17.1%
自由现金流更多
CCNE
多$85.3M
$-26.7M
两年增速更快
CCNE
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.4M | $127.1M |
| 净利润 | $20.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 48.4% | -54.6% |
| 净利率 | 24.0% | — |
| 营收同比 | 45.5% | 17.1% |
| 净利润同比 | 37.4% | — |
| 每股收益（稀释后） | $0.69 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCNEZLAB
| Q4 25 | $86.4M | $127.1M | ||
| Q3 25 | $77.7M | $115.4M | ||
| Q2 25 | $61.2M | $109.1M | ||
| Q1 25 | $56.9M | $105.7M | ||
| Q4 24 | $59.4M | $108.5M | ||
| Q3 24 | $58.5M | $101.8M | ||
| Q2 24 | $54.6M | $100.1M | ||
| Q1 24 | $54.2M | $87.1M |
净利润CCNEZLAB
| Q4 25 | $20.7M | — | ||
| Q3 25 | $20.0M | $-36.0M | ||
| Q2 25 | $14.0M | $-40.7M | ||
| Q1 25 | $11.5M | $-48.4M | ||
| Q4 24 | $15.1M | — | ||
| Q3 24 | $14.0M | $-41.7M | ||
| Q2 24 | $13.0M | $-80.3M | ||
| Q1 24 | $12.6M | $-53.5M |
毛利率CCNEZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CCNEZLAB
| Q4 25 | 48.4% | -54.6% | ||
| Q3 25 | 11.7% | -42.3% | ||
| Q2 25 | 28.2% | -50.3% | ||
| Q1 25 | 25.2% | -53.3% | ||
| Q4 24 | 31.4% | -62.6% | ||
| Q3 24 | 29.6% | -66.6% | ||
| Q2 24 | 29.3% | -76.0% | ||
| Q1 24 | 28.5% | -80.7% |
净利率CCNEZLAB
| Q4 25 | 24.0% | — | ||
| Q3 25 | 25.7% | -31.2% | ||
| Q2 25 | 22.8% | -37.3% | ||
| Q1 25 | 20.2% | -45.8% | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 23.9% | -40.9% | ||
| Q2 24 | 23.7% | -80.2% | ||
| Q1 24 | 23.3% | -61.4% |
每股收益（稀释后）CCNEZLAB
| Q4 25 | $0.69 | $-0.05 | ||
| Q3 25 | $0.69 | $-0.03 | ||
| Q2 25 | $0.61 | $-0.04 | ||
| Q1 25 | $0.50 | $-0.04 | ||
| Q4 24 | $0.67 | $-0.09 | ||
| Q3 24 | $0.61 | $-0.04 | ||
| Q2 24 | $0.56 | $-0.08 | ||
| Q1 24 | $0.55 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $527.9M | $689.6M |
| 总债务越低越好 | $84.9M | — |
| 股东权益账面价值 | $872.1M | $715.5M |
| 总资产 | $8.4B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
现金及短期投资CCNEZLAB
| Q4 25 | $527.9M | $689.6M | ||
| Q3 25 | $438.1M | $717.2M | ||
| Q2 25 | $425.4M | $732.2M | ||
| Q1 25 | $520.2M | $757.3M | ||
| Q4 24 | $443.0M | $779.7M | ||
| Q3 24 | $360.9M | $616.1M | ||
| Q2 24 | $331.1M | $630.0M | ||
| Q1 24 | $301.5M | $650.8M |
总债务CCNEZLAB
| Q4 25 | $84.9M | — | ||
| Q3 25 | $84.8M | — | ||
| Q2 25 | $84.7M | — | ||
| Q1 25 | $84.6M | — | ||
| Q4 24 | $84.6M | — | ||
| Q3 24 | $84.5M | — | ||
| Q2 24 | $84.4M | — | ||
| Q1 24 | $84.3M | — |
股东权益CCNEZLAB
| Q4 25 | $872.1M | $715.5M | ||
| Q3 25 | $844.2M | $759.9M | ||
| Q2 25 | $637.3M | $791.7M | ||
| Q1 25 | $624.5M | $810.8M | ||
| Q4 24 | $610.7M | $840.9M | ||
| Q3 24 | $606.4M | $667.7M | ||
| Q2 24 | $586.7M | $704.2M | ||
| Q1 24 | $578.6M | $762.2M |
总资产CCNEZLAB
| Q4 25 | $8.4B | $1.2B | ||
| Q3 25 | $8.3B | $1.2B | ||
| Q2 25 | $6.3B | $1.2B | ||
| Q1 25 | $6.3B | $1.2B | ||
| Q4 24 | $6.2B | $1.2B | ||
| Q3 24 | $6.0B | $985.3M | ||
| Q2 24 | $5.9B | $987.4M | ||
| Q1 24 | $5.8B | $988.4M |
负债/权益比CCNEZLAB
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $58.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 67.9% | -21.0% |
| 资本支出强度资本支出/营收 | 7.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.14× | — |
| 过去12个月自由现金流最近4个季度 | $91.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CCNEZLAB
| Q4 25 | $65.0M | $-26.0M | ||
| Q3 25 | $7.0M | $-32.0M | ||
| Q2 25 | $20.2M | $-31.0M | ||
| Q1 25 | $11.6M | $-61.7M | ||
| Q4 24 | $71.5M | $-55.8M | ||
| Q3 24 | $26.4M | $-26.8M | ||
| Q2 24 | $10.4M | $-42.2M | ||
| Q1 24 | $12.5M | $-90.1M |
自由现金流CCNEZLAB
| Q4 25 | $58.7M | $-26.7M | ||
| Q3 25 | $4.9M | $-35.0M | ||
| Q2 25 | $17.9M | $-33.9M | ||
| Q1 25 | $9.9M | $-63.2M | ||
| Q4 24 | $55.2M | $-58.4M | ||
| Q3 24 | $22.2M | $-28.2M | ||
| Q2 24 | $4.1M | $-42.9M | ||
| Q1 24 | $10.0M | $-91.1M |
自由现金流率CCNEZLAB
| Q4 25 | 67.9% | -21.0% | ||
| Q3 25 | 6.4% | -30.4% | ||
| Q2 25 | 29.2% | -31.1% | ||
| Q1 25 | 17.3% | -59.9% | ||
| Q4 24 | 93.0% | -53.8% | ||
| Q3 24 | 38.0% | -27.7% | ||
| Q2 24 | 7.6% | -42.9% | ||
| Q1 24 | 18.5% | -104.5% |
资本支出强度CCNEZLAB
| Q4 25 | 7.3% | 0.5% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 3.9% | 2.6% | ||
| Q1 25 | 3.0% | 1.5% | ||
| Q4 24 | 27.4% | 2.4% | ||
| Q3 24 | 7.1% | 1.3% | ||
| Q2 24 | 11.6% | 0.7% | ||
| Q1 24 | 4.5% | 1.1% |
现金转化率CCNEZLAB
| Q4 25 | 3.14× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 4.75× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.81× | — | ||
| Q1 24 | 0.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCNE
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
